Hyperglycemia News and Research RSS Feed - Hyperglycemia News and Research

Hyperglycemia occurs when you have a higher than usual level of glucose in your blood. This can happen shortly after you have eaten a big meal and is not a problem if your glucose level returns to normal. Cells remove glucose from the blood in response toinsulin. If your pancreas doesn't make enough insulin, glucose can't enter the cells and remains in the blood. Blood glucose levels can also get too high if cells areunable to respond to insulin properly (insulinresistance). Without glucose, your cells are unable to make energy and can't function properly.
Integrating fiber optic biosensor into microfluidic chip may help in early diagnosis of diabetes

Integrating fiber optic biosensor into microfluidic chip may help in early diagnosis of diabetes

Insulin deficiency and hyperglycemia are two well-known culprits behind diabetes, both of which are reflected in blood glucose concentrations. Now, researchers are working to create ultrasensitive lab-on-a-chip devices to quickly measure glucose concentrations with the goal of developing device for early diagnosis and prevent of diabetes [More]
Study points to novel way to treat diabetes in some patients

Study points to novel way to treat diabetes in some patients

Blocking the hormone that raises sugar levels in the blood could increase insulin levels while keeping blood sugar levels down. [More]
Gleevec could be novel therapeutic agent for type 2 diabetes

Gleevec could be novel therapeutic agent for type 2 diabetes

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes. [More]
Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

The number of blind people is high. In 2010, the World Health Organisation estimated that, throughout the world, approximately 39 million people are blind. [More]
New article explores effect of frailty on natural history of diabetes

New article explores effect of frailty on natural history of diabetes

Future Science Group today announced the publication of a new article in Future Science OA, reporting data that explore the effect of frailty on the natural history of diabetes and the implications it will have for therapeutic plans in older people. [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
American Diabetes Association issues statement to address diabetes management in LTC facilities

American Diabetes Association issues statement to address diabetes management in LTC facilities

The care of adults over age 65 with type 2 diabetes is a growing concern: the prevalence of diabetes is highest in this age group and is expected to grow as the U.S. population ages, with many needing care at long-term care (LTC) facilities. [More]
Lilly receives FDA approval for Humulin R U-500 KwikPen

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin. [More]
Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers to undertake long-term clinical trial of artificial pancreas system for type 1 diabetes patients

Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

Mayo Clinic researchers report national trend toward overtesting HbA1C levels in diabetes patients

In a study released online today in The BMJ, researchers from Mayo Clinic report a national trend toward overtesting glycated hemoglobin (HbA1C) levels in adult patients with Type 2 diabetes. [More]
T1DM therapeutics market expected to reach $7.1 billion by 2021

T1DM therapeutics market expected to reach $7.1 billion by 2021

Analysis from business intelligence provider GBI Research - Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - states that the global market value for T1DM treatment will rise from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Gestational diabetes mellitus screening provides more health benefits to pregnant women

Gestational diabetes mellitus screening provides more health benefits to pregnant women

A local research study conducted by KK Women's and Children's Hospital and Duke-NUS Graduate Medical School has found that pregnant patients benefit most from gestational diabetes mellitus (GDM) screening as it allows for timely interventions and brings about health benefits that far outweigh the cost. [More]
Study explores diabetes screening for patients with severe mental illness

Study explores diabetes screening for patients with severe mental illness

A study just published in the Journal of the American Medical Association Internal Medicine examines diabetes screening for patients with severe mental illness, who are two to three times more likely to have type 2 diabetes than the general population. More than seven million Americans in the United States have severe mental illness, and there are many factors contributing to their increased risk of getting diabetes, including treatment with antipsychotic medication. [More]
Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

Pharmacy-led glycemic control program improves outcomes for surgical patients with diabetes

A pharmacy-led glycemic control program is linked to improved outcomes for surgical patients with diabetes and those who develop stress-induced hyperglycemia or high blood sugars as a result of surgery, according to a new Kaiser Permanente study published in the American Journal of Pharmacy Benefits. [More]
Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes. [More]
LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, announced today that Enstilar has been approved by the U.S. Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older. [More]
Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.35 million federal grant to study how emulsifiers affect bacteria in the intestinal tract and cause chronic inflammatory diseases in the gut. [More]
Advertisement